A single dose of neoadjuvant nivolumab, ipilimumab and relatlimab increased the diversity, abundance and activation of TILs in the posttreatment tumor compared with the baseline tumor in newly diagnosed MGMT promoter unmethylated GBM. Here, MGMT is linked to neoplasm.